Overview

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Status:
Enrolling by invitation
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.
Phase:
Phase 2
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc.